Ticker brief
ABVX ABIVAX SA-ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$88.01
1 day
-2.5%
14 days
-0.2%
mkt cap
$11.5B
signals 14d
17
authors 14d
9
crowd 14d
-0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 62% cheap · 12 pctile own 1y | IV/HV 1.36× |
| Skew — 25Δ RR 30d | +0.017 27 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +7.51 elevated | 5-session Δ -1.30 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-07-01 (z=2.5) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-16 · now +0.15 (−1 bearish … +1 bullish)
Who spoke9
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MitchMartan98 | C | -3.79 | 4 | +0.50 |
| @Pharmdca | C | -3.41 | 3 | +0.53 |
| @bioinvestor24 | A | -0.87 | 3 | -0.27 |
| @semodough | C | -1.06 | 2 | +0.08 |
| @RevShark | B | +1.92 | 1 | -0.55 |
| @TheNewMoney_app | C | · | 1 | -0.30 |
| @Maximus_Holla | C | -2.13 | 1 | +0.65 |
| @Omnitrader69 | C | -2.17 | 1 | +0.35 |
| @markflowchatter | B | -0.76 | 1 | +0.15 |
Recent signals17of 17 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @markflowchatter | +0.15 | Ranks biotech names by perceived M&A likelihood, with VKTX and MDGL least likely. | -0.1% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | -0.45 | Rejects exaggerated demand and acquisition claims for ABVX, citing side-effect and malignancy concerns. | -4.7% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | -0.35 | Questions why Lilly would pay more than $15 billion for ABVX given the shift toward combination and long-acting injectables. | -4.7% | tweet ↗ |
| 2026-10-15 | @Omnitrader69 | +0.35 | Notes ABVX returning to 90 and suggests beaten-down biotechnology stocks may rebound. | -4.7% | tweet ↗ |
| 2026-10-14 | @Maximus_Holla | +0.65 | Make a likely final ABVX add and manage risk against recent lows. — Explicit add with a stated risk reference, though the chart supplies the exact level. | +0.0% | tweet ↗ |
| 2026-10-13 | @MitchMartan98 | +0.65 | Biotech remains weak, but the author likes six named stocks at current levels. | +2.1% | tweet ↗ |
| 2026-10-12 | @TheNewMoney_app | -0.30 | Reports a large purchase of ABVX Jan 2028 $50 puts. | +1.2% | tweet ↗ |
| 2026-10-10 | @bioinvestor24 | +0.00 | Reiterates that shorting Moderna was a mistake while referencing a prior ABVX mechanism discussion. | -0.2% | tweet ↗ |
| 2026-10-10 | @MitchMartan98 | +0.50 | Lists stocks the author believes offer attractive upside asymmetry now. | -0.2% | tweet ↗ |
| 2026-10-09 | @semodough | +0.15 | Questions KYMR's valuation at 10x CRVS, 7x NKTR and 1.5x ABVX. | -0.2% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.65 | Selectively buying biotech names during the pullback. — Explicitly discloses ongoing purchases; ticker output is capped at six. | -1.2% | tweet ↗ |
| 2026-10-07 | @Pharmdca | +0.70 | Discloses share purchases in AVR above $6 and ABVX above $86. | +1.1% | tweet ↗ |
| 2026-10-07 | @MitchMartan98 | +0.45 | Tongue-in-cheek request for Lilly to acquire ABVX, implying value in ABVX. | +1.1% | tweet ↗ |
| 2026-10-06 | @MitchMartan98 | +0.40 | Creates a biotech watchlist of quality names after sharp declines. | -0.2% | tweet ↗ |
| 2026-10-06 | @Pharmdca | +0.25 | Argues biotech is showing classic late-stage capitulation and bottom-forming conditions. | -0.2% | tweet ↗ |
| 2026-10-06 | @RevShark | -0.55 | Reports widespread biotech breakdowns across IBB and several constituent names. | -0.2% | tweet ↗ |
| 2026-10-06 | @semodough | +0.00 | Sees PCVX as a rare biotech asset with $8–10B revenue potential while acknowledging execution remains. | -0.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.